A clinical trial was recruiting patients with recurrent anaplastic astrocytoma (AA), a grade 3 glioma. The study was being conducted across the United States as well as in a number of European countries. AA affects about five to eight per 100,000 people, and in order to qualify these patients must be experiencing their first recurrence or progression after surgical resection or chemotherapy treatment.
Case Study